Add BrightSurf on Google Email

Science News for July 22, 2017


World-first ketamine trial shows promise for geriatric depression

Researchers have conducted the world's first randomised control trial assessing ketamine's effectiveness as an antidepressant in elderly patients. The trial found that repeated intravenous doses of ketamine resulted in a 68.8% response and remission rate among patients, with no severe side effects reported.

SourceUniversity of New South Wales·JournalAmerican Journal of Geriatric Psychiatry·DateJul 22, 2017